DrugRisk Announces New Information Showing Yaz Settlements May Be Increasing

December 22, 2012

The Drug Resource Center is the Web´s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com.

Dallas, TX (PRWEB) December 21, 2012

Online prescription drug resource center DrugRisk.com has added information to its already comprehensive database which indicates German drug maker Bayer may be stepping up efforts to resolve claims against Yaz and Yasmin birth control, possibly even paying more per case that before.

“The DrugRisk goal has always been to educate the public with the latest updates on prescription drug warnings, recalls, studies and litigation. In reviewing the latest financial records of Bayer, we noticed an increased reported average case value for Yaz lawsuits, as well as an indication of what cases the company is seeking to resolve,” said DrugRisk representative Ryan Mayer.

The latest Bayer shareholder report indicates they continue to settle claims that Yaz and Yasmin caused blood clots, resolving approximately 3,500 Yaz lawsuits so far at a total cost of nearly $750 million.* This average of approximately $214,000 per case was slightly higher than the $212,000 previously reported by Bloomberg News on July 31, 2012.

DrugRisk also learned that the company confirmed in the report they are only settling claims involving blood clot injuries, such as deep vein thrombosis and pulmonary embolism.

The resource center had previously added a new warning by the American College of Obstetricians and Gynecologists that birth control pills containing drospirenone, such as Yaz and Yasmin, may have a higher risk of causing blood clots.**

Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking Yaz or Yasmin is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options.

DrugRisk has learned that Yaz lawsuits are being consolidated to a special federal Multi-District Litigation court in Illinois. The formal case is known as Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois).

The Drug Risk Resource Center cautions victims who wish to learn about their legal options that they should seek a lawyer with experience in defective drug litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.

For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*Bayer Interim Financial Statement, Legal Notes and Business Development, September 30, 2012

**Chicago Tribune October 24, 2012, “Newer Pill has low blood clot risk: ob-gyn group”

For the original version on PRWeb visit: http://www.prweb.com/releases/prwebyaz-lawsuits/settlement-information/prweb10262533.htm

Source: prweb

comments powered by Disqus